Key result
Admission plasma MIF levels were elevated in 68% of STEMI patients and significantly correlated with CMR-derived infarct size, ventricular volumes, and ejection fraction (r=0.46 to 0.77, P<0.01).
Why the study?
Does admission plasma macrophage migration inhibitory factor (MIF) level predict infarct size and cardiac remodeling in patients with STEMI?
Observational (n=374)
Does admission plasma macrophage migration inhibitory factor (MIF) level predict infarct size and cardiac remodeling in patients with STEMI?
Effect estimate: r = 0.46 to 0.77
p-value: p=< 0.01
Plasma MIF levels measured at admission in STEMI patients are predictive of final infarct size and the extent of cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
May inform early STEMI risk stratification; hypothesis-generating and should not yet change practice pending prospective validation.
Chan et al. (2013) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=374). Admission plasma macrophage migration inhibitory factor (MIF) levels vs. Healthy controls and other biomarkers was evaluated on Correlation with CMR-derived infarct size, ventricular volumes and ejection fraction (r = 0.46 to 0.77, p=< 0.01). Admission plasma MIF levels were elevated in 68% of STEMI patients and significantly correlated with CMR-derived infarct size, ventricular volumes, and ejection fraction (r=0.46 to 0.77, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: